![]() ![]() ![]() Initial: 150 mg/day in divided doses maximum dose: 600 mg/day (inpatients) 400 mg/day (outpatients).Įxtended release: Initial: 150 mg once daily at bedtime may increase by 75 mg/day at intervals no less than every 3 days based on response, tolerability, and severity of symptoms maximum dose: 375 mg/dayĭiscontinuation of therapy:Due to its short half-life, withdrawal symptoms are likely with abrupt discontinuation. Manufacturer’s labeling: Dosing in prescribing information may not reflect current clinical practice. Note: Adverse effects are increased with doses >400 mg/day and are not recommended in patients with cardiovascular disease sedative effects may be better tolerated by dividing the daily dose to give a smaller dose in daytime and larger dose before bedtime ( Ref). Thereafter may further increase by 50 to 100 mg/day every 2 to 4 weeks based on response and tolerability usual dosage range 200 to 400 mg/day maximum 600 mg/day. Immediate release: Initial: 50 mg twice daily may increase in increments of 50 mg/day every 3 to 7 days to a target dose of 75 to 150 mg twice daily. Major depressive disorder (unipolar) (alternative agent): Oral: Consult drug interactions database for more information. If intolerable withdrawal symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate ( Ref).ĭosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. APA and NICE guidelines suggest tapering therapy over at least several weeks with consideration to the half-life of the drug drugs with a shorter half-life may need to be tapered more conservatively. Evidence supporting ideal taper rates is limited. Migraine, prophylaxis: Limited data available: Note: Efficacy results variable expert recommendations for migraine prevention in children and adolescents do not suggest trazodone as a routine therapeutic option ( Ref).Ĭhildren ≥7 years and Adolescents: Oral: Immediate-release formulation: 1 mg/kg/ day in 3 divided doses maximum dose: 150 mg/dose ( Ref).ĭiscontinuation of therapy: Due to short half-life of trazodone, avoid abrupt discontinuation to minimize the incidence of withdrawal symptoms, rebound insomnia, or increased nightmares as a result of REM sleep rebound. Note: Pharmacokinetic analysis based on simulation reported that the following age-dependent pediatric doses resulted in exposures similar to adult doses of 30 to 150 mg/day: Children >6 to 12 years: 0.4 to 1.9 mg/kg/day and Adolescents: 0.4 to 2.1 mg/kg/day ( Ref) experiential data are needed to fully assess. When used for palliative care, multiple daily doses may be necessary in patients >18 years of age, 25 to 50 mg/dose increased gradually to twice or 3 times daily as needed (do not exceed adult dosing) ( Ref). ![]() Due to possible risk of QT prolongation, it is suggested to avoid or use with caution in patients with Rett syndrome ( Ref).Ĭhildren 18 months to 5 years and Adolescents: Oral: Immediate release: Initial: 0.75 to 1 mg/kg/dose or 25 to 50 mg at bedtime may increase at 2-week intervals in 12.5 to 25 mg increments up to a maximum dose of 200 mg/dose reported range: 0.5 to 2 mg/kg/ day ( Ref). Insomnia sleep disturbances: Limited data available frequently used clinically in children with comorbid neuropsychiatric disorders (eg, autistic spectrum disorders, neurogenetic disorders, mood disorders, anxiety disorders, developmental delay with attention-deficit hyperactivity disorder) ( Ref). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |